3 Reasons Amgen Inc.'s Stock Could Fall

Amgen may have plenty of late-stage catalysts on the horizon, but these three factors could negate that optimism and push its stock lower.

Aug 26, 2014 at 9:43AM

Years of patience are finally paying off for Amgen (NASDAQ:AMGN) shareholders, whose shares jump by more than 160% over the past three years.

AMGN Chart

AMGN data by YCharts

Amgen's shares have rallied on the prospect of delivering late-stage data on 10 new compounds before the end of 2016, as well as its aggressive purchase of Onyx Pharmaceuticals for $10.4 billion, which Wall Street expects will put some pep in Amgen's step.

But what stakeholders may fail to realize is that headwinds exist in Amgen, as they do with every stock, which could knock it off its recent pedestal and send its shares lower. Of course, you won't find these headwinds from reading a simple earnings report. Instead, you need to look deeper, beyond just the headline figures, to discover what factors might work against Amgen achieving its goals.

Today we're going to look at three catalysts that I suspect are most likely to send Amgen's stock lower. But before we do that, it's important to remind readers that stocks can go up just as easily as they can go down. As you read this bearish thesis here today, keep the other side of the coin in mind, and understand that just because a company faces challenges doesn't mean that it necessarily will see its share price head lower.

Kyprolis, Kyprolis, Kyprolis!
You are reading that correctly. Just as multiple myeloma drug Kyprolis was singled out as one of the primary catalysts that could send Amgen higher, it's also a factor that could lead to its stock falling considerably from its current price.

G

Source: Deutsche Bank Healthcare Conference presentation / Amgen

Amgen's Kyprolis, which was acquired when it bought Onyx Pharmaceuticals, is on pace to deliver close to $350 million in revenue this year, but is looked upon by Wall Street as a drug with peak annual sales potential of between $2 billion and $3 billion. In order to hit these lofty annual figures Kyprolis needs to see its label expand beyond its current Food and Drug Administration-approved indication of treating third-line multiple myeloma and into second-line multiple myeloma and small-cell lung cancer.

"What might the hold-up be in that expansion?" you ask? The answer to that lies in the company's recently announced FOCUS study. As Amgen noted earlier this month, Kyprolis missed its primary endpoint of a statistically significant improvement in overall survival in second-line multiple myeloma patients, although in the ASPIRE study it showed a notable improvement of 8.7 months in progression-free survival over the control group. In addition, even though treatment discontinuation was similar in both arms of the FOCUS study, there was a notable increase in renal adverse events in the Kyprolis arm during the late-stage study. 

Though Amgen feels confident the ASPIRE data should be enough to get Kyprolis the critical second-line indication in the U.S. and EU, the European Medicines Agency is a particular stickler when it comes to experimental drugs demonstrating improvements in overall survival. This could make an approval tougher to come by, especially in Europe, and it could stymie Kyprolis' sales growth.

Questionable faith in Amgen's management
The second factor that I suspect could play a role in pushing Amgen's stock lower is investors' lack of faith in management to take the company down the right path.

On one hand, Bob Bradway, the current CEO of Amgen, has only been leading the company as CEO since May 2012. In the time since he took over shares have doubled. A great number of existing shareholders won't complain about that performance.

But look back more than three years and you'll see a more mixed picture.

AMGN Chart

AMGN data by YCharts

Between 2000 and 2012 Amgen investors essentially witnessed their stock trade nominally flat. Of course, Amgen was also buying back shares and, as we've seen in recent years, paying out a dividend to provide a reward for faithful investors. 

Although Bradway was clear during the company's conference call that Amgen is a well-oiled machine from both an internal and external pipeline status, the historic figures speak for themselves and point to a management team that's failed to exceed investors' expectations for a long time.

Little ex-U.S. exposure
Lastly, and this topic gets very little exposure, Amgen is heavily reliant on the U.S. for its growth. In fact, I'd say too reliant.

Images

Source: Bryan Pocius via Flickr

In the second quarter, Amgen reported total product sales of $4.95 billion, an 8% increase over the previous year. The company's U.S. sales, however, accounted for $3.76 billion, or 76% of total sales.

It's not all bad news that Amgen's largest market is the United States. In fact, a good number of drugmakers would refer to the U.S. as their primary revenue source. Yet Amgen's rest-of-world category, which includes Europe and other emerging markets, managed just $1.19 billion in product sales. This ROW category is what includes the possibility of faster-growth markets than the U.S., and also allows Amgen some geographic diversity in case another economic downturn in the U.S. causes consumers to cut back on spending.

Let's not forget, as well, that insurers in the U.S. are potentially seeing their margins pinched by the implementation of the Affordable Care Act (you may know it better as Obamacare). In response to the uncertainties associated with Obamacare and the expectation of higher medical costs, insurers and pharmacy-benefit management companies have gone on the offensive against big pharma and biotech companies in an effort to keep drug prices from soaring. In some cases it's resulted in select insurers dropping coverage on popular drugs because their selling price was simply too high. Being so focused on the U.S. market Amgen is potentially susceptible to these pricing pressures, which full-well could weigh on its stock.

Tying things together
Amgen's been a welcome holding for investors over the past three years, but these three headwinds might imply that it's run is about to come to a grinding halt. With plenty of late-stage catalysts on the horizon, but the quality of its Onyx purchase, its lack of geographic diversity, and its history of weak growth also in the forefront, it gives current investors, and those on the outside looking in, some serious catalysts to mull over.

Though Amgen may be trying to reinvent itself, it's this revolutionary technology that everyone's soon going to be talking about!
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers